TScan Therapeutics Revenue and Competitors

Boston, MA USA

Location

$137.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • TScan Therapeutics's estimated annual revenue is currently $18.9M per year.(i)
  • TScan Therapeutics's estimated revenue per employee is $105,642
  • TScan Therapeutics's total funding is $137.5M.

Employee Data

  • TScan Therapeutics has 179 Employees.(i)
  • TScan Therapeutics grew their employee count by 23% last year.

TScan Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Medical OfficerReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
Chief StaffReveal Email/Phone
5
VP, Clinical DevelopmentReveal Email/Phone
6
SVP, Technical Operations and QualityReveal Email/Phone
7
VP Clinical OperationsReveal Email/Phone
8
VP, Investor RelationsReveal Email/Phone
9
VP Process SciencesReveal Email/Phone
10
SVP, Medical, Translational MedicineReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M82-45%$107.3MN/A
#2
$0.2M1-50%N/AN/A
#3
$6.2M4021%N/AN/A
#4
$42.2M2184%$165MN/A
#5
$14.6M94-37%$312.8MN/A
#6
$0.3M2-67%N/AN/A
#7
$235M366-5%$340.9MN/A
#8
$56M289-7%$7.6MN/A
#9
$4.7M6136%N/AN/A
#10
$2M138%N/AN/A
Add Company

What Is TScan Therapeutics?

Harnessing novel T cell systems to extend the promise of immunotherapy

keywords:N/A

$137.5M

Total Funding

179

Number of Employees

$18.9M

Revenue (est)

23%

Employee Growth %

N/A

Valuation

N/A

Accelerator

TScan Therapeutics News

2022-04-13 - TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Up ...

HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of TScan Therapeutics in a report on Thursday, March 10th. One...

2022-04-06 - Tscan Therapeutics (TCRX) Stock: Why The Price Surged 17.83%

The stock price of Tscan Therapeutics Inc (NASDAQ: TCRX) increased by 17.83% in the most recent trading session. This is why.

2022-04-06 - TScan Therapeutics Appoints Leiden Dworak, CPA, MBA, as ...

WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company...

2021-08-19 - TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy Candidates, TSC-100 and TSC-101 WALTHAM, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- TScan Thera ...

2021-01-25 - TScan Therapeutics Raises $100M in Series C Financing

TScan Therapeutics, a Waltham, Mass.-based biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies in oncology, closed a $100m Series C financing. Backers included new investors BlackRock, RA Capital Management, and two undisclosed healthcare-fo ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$27.6M17922%N/A
#2
$46.3M1807%N/A
#3
$35.1M181-10%$227M
#4
$35.3M18218%$125.4M
#5
$66.1M18517%N/A